KeyBanc analyst Brett Fishbin has revised the price target for ResMed (RMD, Financial), adjusting it downward from $280 to $268. Despite this adjustment, the analyst maintains an Overweight rating on the shares.
The decision to lower the price target comes as the firm considers broader economic factors, including potential impacts from tariffs and the looming threat of a recession. These macroeconomic concerns have prompted KeyBanc to reevaluate price targets for several companies, even as the fundamental trends within the MedTech sector remain largely positive as the first-quarter earnings season approaches.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for ResMed Inc (RMD, Financial) is $263.95 with a high estimate of $295.00 and a low estimate of $195.00. The average target implies an upside of 23.97% from the current price of $212.91. More detailed estimate data can be found on the ResMed Inc (RMD) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, ResMed Inc's (RMD, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ResMed Inc (RMD, Financial) in one year is $287.86, suggesting a upside of 35.2% from the current price of $212.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ResMed Inc (RMD) Summary page.
